-
1
-
-
77955635233
-
Cancer statistics, 2010
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
0033958595
-
The prostate: Diagnostic evaluation of metastatic disease
-
Yu KK, Hawkins RA. The prostate: diagnostic evaluation of metastatic disease. Radiol Clin North Am. 2000; 38: 139-157, ix.
-
(2000)
Radiol Clin North Am
, vol.38
-
-
Yu, K.K.1
Hawkins, R.A.2
-
3
-
-
33947258834
-
Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy
-
Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007; 51: 1175-1184.
-
(2007)
Eur Urol
, vol.51
, pp. 1175-1184
-
-
Simmons, M.N.1
Stephenson, A.J.2
Klein, E.A.3
-
4
-
-
34547655304
-
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy
-
Sandler HM, Eisenberger MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol. 2007; 178: S20-S24.
-
(2007)
J Urol
, vol.178
-
-
Sandler, H.M.1
Eisenberger, M.A.2
-
5
-
-
39749137117
-
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
-
Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008; 26: 842-847.
-
(2008)
J Clin Oncol
, vol.26
, pp. 842-847
-
-
Ross, R.W.1
Oh, W.K.2
Xie, W.3
Pomerantz, M.4
Nakabayashi, M.5
Sartor, O.6
-
6
-
-
4744347762
-
Mechanisms of androgen-refractory prostate cancer
-
Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004; 351: 1488-1490.
-
(2004)
N Engl J Med
, vol.351
, pp. 1488-1490
-
-
Debes, J.D.1
Tindall, D.J.2
-
7
-
-
1842612441
-
Molecular determinants of resistance to antiandrogen therapy
-
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10: 33-39.
-
(2004)
Nat Med
, vol.10
, pp. 33-39
-
-
Chen, C.D.1
Welsbie, D.S.2
Tran, C.3
Baek, S.H.4
Chen, R.5
Vessella, R.6
-
8
-
-
0035496220
-
The development of androgen independent prostate cancer
-
Feldman BJ, Feldman D. The development of androgen independent prostate cancer. Nat Rev Cancer. 2001; 1: 34-45.
-
(2001)
Nat Rev Cancer
, vol.1
, pp. 34-45
-
-
Feldman, B.J.1
Feldman, D.2
-
9
-
-
0034671668
-
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
-
Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000; 60: 6841-6845.
-
(2000)
Cancer Res
, vol.60
, pp. 6841-6845
-
-
Wen, Y.1
Hu, M.C.2
Makino, K.3
Spohn, B.4
Bartholomeusz, G.5
Yan, D.H.6
-
10
-
-
7944234374
-
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability
-
Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat, J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004; 6: 517-527.
-
(2004)
Cancer Cell
, vol.6
, pp. 517-527
-
-
Mellinghoff, I.K.1
Vivanco, I.2
Kwon, A.3
Tran, C.4
Wongvipat, J.5
Sawyers, C.L.6
-
11
-
-
77953120700
-
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy
-
Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, Walsh PC. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. J Urol. 2010; 184: 157-161.
-
(2010)
J Urol
, vol.184
, pp. 157-161
-
-
Loeb, S.1
Makarov, D.V.2
Schaeffer, E.M.3
Humphreys, E.B.4
Walsh, P.C.5
-
12
-
-
34547903643
-
Blood biomarkers for prostate cancer detection and prognosis
-
Shariat SF, Karam JA, Roehrbom CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol. 2007; 3: 449-461.
-
(2007)
Future Oncol
, vol.3
, pp. 449-461
-
-
Shariat, S.F.1
Karam, J.A.2
Roehrbom, C.G.3
-
13
-
-
68549090701
-
New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era
-
Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Anticancer Res. 2009; 29: 3289-3298.
-
(2009)
Anticancer Res
, vol.29
, pp. 3289-3298
-
-
Bickers, B.1
Aukim-Hastie, C.2
-
14
-
-
0034600849
-
The ErbB signaling network: Receptor heterodimerization in development and cancer
-
Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19: 3159-3167.
-
(2000)
EMBO J
, vol.19
, pp. 3159-3167
-
-
Olayioye, M.A.1
Neve, R.M.2
Lane, H.A.3
Hynes, N.E.4
-
16
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712.
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
Holt, J.A.4
Wong, S.G.5
Keith, D.E.6
-
17
-
-
0025281906
-
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
-
Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990; 50: 4087-4091.
-
(1990)
Cancer Res
, vol.50
, pp. 4087-4091
-
-
Berchuck, A.1
Kamel, A.2
Whitaker, R.3
Kerns, B.4
Olt, G.5
Kinney, R.6
-
18
-
-
0025804023
-
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
-
Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991; 11: 117-127.
-
(1991)
J Clin Immunol
, vol.11
, pp. 117-127
-
-
Shepard, H.M.1
Lewis, G.D.2
Sarup, J.C.3
Fendly, B.M.4
Maneval, D.5
Mordenti, J.6
-
19
-
-
0033118889
-
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of 20 human breast cancers
-
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of 20 human breast cancers. Oncogene. 1999; 18: 2241-2251.
-
(1999)
Oncogene
, vol.18
, pp. 2241-2251
-
-
Pegram, M.1
Hsu, S.2
Lewis, G.3
Pietras, R.4
Beryt, M.5
Sliwkowski, M.6
-
20
-
-
0032825577
-
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
-
Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol. 1999; 26: 89-95.
-
(1999)
Semin Oncol
, vol.26
, pp. 89-95
-
-
Pegram, M.D.1
Slamon, D.J.2
-
21
-
-
3242730201
-
Her-2/neu expression in prostate cancer: A dynamic process?
-
Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, et al. Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res. 2004; 10: 4742-4745.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4742-4745
-
-
Carles, J.1
Lloreta, J.2
Salido, M.3
Font, A.4
Suarez, M.5
Baena, V.6
-
22
-
-
0000153682
-
The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
-
Mass R, Sanders C, Kasian C, Johnson L, Everett T, Anderson S. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol. 2000; 19: 75a.
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
-
-
Mass, R.1
Sanders, C.2
Kasian, C.3
Johnson, L.4
Everett, T.5
Anderson, S.6
-
23
-
-
0028955388
-
Epidermal growth factor-related peptides and their receptors in human malignancies
-
Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183-232.
-
(1995)
Crit Rev Oncol Hematol
, vol.19
, pp. 183-232
-
-
Salomon, D.S.1
Brandt, R.2
Ciardiello, F.3
Normanno, N.4
-
24
-
-
0036847724
-
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
-
Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002; 8: 3438-3444.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3438-3444
-
-
Di Lorenzo, G.1
Tortora, G.2
D'Armiento, F.P.3
De Rosa, G.4
Staibano, S.5
Autorino, R.6
-
25
-
-
11144322016
-
Expression patterns of potential therapeutic targets in prostate cancer
-
Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113:619-628.
-
(2005)
Int J Cancer
, vol.113
, pp. 619-628
-
-
Zellweger, T.1
Ninck, C.2
Bloch, M.3
Mirlacher, M.4
Koivisto, P.A.5
Helin, H.J.6
-
26
-
-
0034808673
-
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
-
Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001; 7: 2643-2647.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2643-2647
-
-
Osman, I.1
Scher, H.I.2
Drobnjak, M.3
Verbel, D.4
Morris, M.5
Agus, D.6
-
27
-
-
0034767009
-
HER2 protein expression and gene amplification in androgen-independent prostate cancer
-
Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol. 2001; 116: 234-239.
-
(2001)
Am J Clin Pathol
, vol.116
, pp. 234-239
-
-
Reese, D.M.1
Small, E.J.2
Magrane, G.3
Waldman, F.M.4
Chew, K.5
Sudilovsky, D.6
-
28
-
-
0033022342
-
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase
-
Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nat Med. 1999; 5: 280-285.
-
(1999)
Nat Med
, vol.5
, pp. 280-285
-
-
Craft, N.1
Shostak, Y.2
Carey, M.3
Sawyers, C.L.4
-
29
-
-
0034614108
-
Her-2-neu expression and progression toward androgen independence in human prostate cancer
-
Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000; 92: 1918-1925.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 1918-1925
-
-
Signoretti, S.1
Montironi, R.2
Manola, J.3
Altimari, A.4
Tam, C.5
Bubley, G.6
-
30
-
-
33745862393
-
Prognostic significance of immunohistochemical expression of the Her-2/neu oncoprotein in bone metastatic prostate cancer
-
Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, et al. Prognostic significance of immunohistochemical expression of the Her-2/neu oncoprotein in bone metastatic prostate cancer. Urology. 2006; 68: 110-115.
-
(2006)
Urology
, vol.68
, pp. 110-115
-
-
Nishio, Y.1
Yamada, Y.2
Kokubo, H.3
Nakamura, K.4
Aoki, S.5
Taki, T.6
-
31
-
-
0032794761
-
Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer
-
Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr, Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int J Cancer. 1999; 84: 421-425.
-
(1999)
Int J Cancer
, vol.84
, pp. 421-425
-
-
Morote, J.1
de Torres, I.2
Caceres, C.3
Vallejo, C.4
Schwartz Jr., S.5
Reventos, J.6
-
32
-
-
33745255349
-
Androgen-dependent regulation of Her-2/neu in prostate cancer cells
-
Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006; 66: 5723-5728.
-
(2006)
Cancer Res
, vol.66
, pp. 5723-5728
-
-
Berger, R.1
Lin, D.I.2
Nieto, M.3
Sicinska, E.4
Garraway, L.A.5
Adams, H.6
-
33
-
-
0034833701
-
Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease
-
Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol. 2001; 166: 1514-1519.
-
(2001)
J Urol
, vol.166
, pp. 1514-1519
-
-
Shi, Y.1
Brands, F.H.2
Chatterjee, S.3
Feng, A.C.4
Groshen, S.5
Schewe, J.6
-
34
-
-
3242755999
-
Molecular alterations associated with LNCaP cell progression to androgen independence
-
Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, et al. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate. 2004; 60: 257-271.
-
(2004)
Prostate
, vol.60
, pp. 257-271
-
-
Shi, X.B.1
Ma, A.H.2
Tepper, C.G.3
Xia, L.4
Gregg, J.P.5
Gandour-Edwards, R.6
-
35
-
-
1342280433
-
Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence
-
Hernes E, Fosså SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer. 2004; 90: 449-454.
-
(2004)
Br J Cancer
, vol.90
, pp. 449-454
-
-
Hernes, E.1
Fosså, S.D.2
Berner, A.3
Otnes, B.4
Nesland, J.M.5
-
36
-
-
77956629278
-
Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis
-
Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, et al. Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol. 2010; 184: 842-850.
-
(2010)
J Urol
, vol.184
, pp. 842-850
-
-
Neto, A.S.1
Tobias-Machado, M.2
Wroclawski, M.L.3
Fonseca, F.L.4
Teixeira, G.K.5
Amarante, R.D.6
-
37
-
-
2342456382
-
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: Final results from the California Cancer Consortium Screening and Phase II Trial
-
Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004; 100: 2125-2131.
-
(2004)
Cancer
, vol.100
, pp. 2125-2131
-
-
Lara Jr., P.N.1
Chee, K.G.2
Longmate, J.3
Ruel, C.4
Meyers, F.J.5
Gray, C.R.6
-
38
-
-
3943104783
-
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
-
Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004; 60: 332-337.
-
(2004)
Prostate
, vol.60
, pp. 332-337
-
-
Ziada, A.1
Barqawi, A.2
Glode, L.M.3
Varella-Garcia, M.4
Crighton, F.5
Majeski, S.6
-
39
-
-
33846927744
-
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapynaive patients with hormone-refractory prostate cancer
-
de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapynaive patients with hormone-refractory prostate cancer. J Clin Oncol. 2007; 25: 257-262.
-
(2007)
J Clin Oncol
, vol.25
, pp. 257-262
-
-
de Bono, J.S.1
Bellmunt, J.2
Attard, G.3
Droz, J.P.4
Miller, K.5
Flechon, A.6
-
40
-
-
0037790997
-
Purification of Her-2 extracellular domain and identification of its cleavage site
-
Yuan CX, Lasut AL, Wynn R, Neff NT, Hollis GF, Ramaker ML, et al. Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expr Purif. 2003; 29: 217-222.
-
(2003)
Protein Expr Purif
, vol.29
, pp. 217-222
-
-
Yuan, C.X.1
Lasut, A.L.2
Wynn, R.3
Neff, N.T.4
Hollis, G.F.5
Ramaker, M.L.6
-
41
-
-
38849155715
-
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel
-
Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, et al. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol. 2008; 19: 269-275.
-
(2008)
Ann Oncol
, vol.19
, pp. 269-275
-
-
Domingo-Domenech, J.1
Fernandez, P.L.2
Filella, X.3
Martinez-Fernandez, A.4
Molina, R.5
Fernandez, E.6
-
42
-
-
0028170155
-
Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
-
Myers RB, Srivastava S, Oelschlager DK, Grizzle WE. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst. 1994; 86: 1140-1145.
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 1140-1145
-
-
Myers, R.B.1
Srivastava, S.2
Oelschlager, D.K.3
Grizzle, W.E.4
-
43
-
-
0036625856
-
Serum HER-2/neu extracellular domain levels in men presenting with suspected prostate cancer
-
Croal BL, Mitchell IDC, Mutch WJ, Dickie A, Cohen N, Ross IS. Serum HER-2/neu extracellular domain levels in men presenting with suspected prostate cancer. UroOncology 2002; 2:99-102.
-
(2002)
UroOncology
, vol.2
, pp. 99-102
-
-
Croal, B.L.1
Mitchell, I.D.C.2
Mutch, W.J.3
Dickie, A.4
Cohen, N.5
Ross, I.S.6
-
44
-
-
34848863777
-
Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer
-
Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, et al. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res. 2007; 13: 5377-5384.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5377-5384
-
-
Shariat, S.F.1
Bensalah, K.2
Karam, J.A.3
Roehrborn, C.G.4
Gallina, A.5
Lotan, Y.6
-
45
-
-
33748769249
-
Pretreatment serum level of HER2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy
-
Okegawa T, Kinjo M, Nutahara K, HIigashihara E. Pretreatment serum level of HER2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol. 2006; 13: 1197-1201.
-
(2006)
Int J Urol
, vol.13
, pp. 1197-1201
-
-
Okegawa, T.1
Kinjo, M.2
Nutahara, K.3
Hiigashihara, E.4
-
46
-
-
0030888544
-
C-erbB-2 oncoprotein: A potential biomarker of advanced prostate cancer
-
Arai Y, Yoshiki T, Yoshida O. C-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate. 1997; 30: 195-201.
-
(1997)
Prostate
, vol.30
, pp. 195-201
-
-
Arai, Y.1
Yoshiki, T.2
Yoshida, O.3
-
47
-
-
0023834161
-
Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
-
Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988; 61: 195-202.
-
(1988)
Cancer
, vol.61
, pp. 195-202
-
-
Soloway, M.S.1
Hardeman, S.W.2
Hickey, D.3
Raymond, J.4
Todd, B.5
Soloway, S.6
-
48
-
-
0037316605
-
Matrix metalloproteinases, angiogenesis, and cancer: Commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor
-
Clin. Cancer Res., 9: 00-00, 2003
-
Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003. Clin Cancer Res. 2003; 9: 551-554.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 551-554
-
-
Rundhaug, J.E.1
-
49
-
-
64549128211
-
Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer
-
Tambo M, Higashihara E, Terado Y, Nutahara K, Okegawa T. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int J Urol. 2009; 16: 369-374.
-
(2009)
Int J Urol
, vol.16
, pp. 369-374
-
-
Tambo, M.1
Higashihara, E.2
Terado, Y.3
Nutahara, K.4
Okegawa, T.5
-
50
-
-
0036294369
-
C-erbB2 oncoprotein and its soluble ectodomain: A new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment
-
Wu JT. C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta. 2002; 322: 11-19.
-
(2002)
Clin Chim Acta
, vol.322
, pp. 11-19
-
-
Wu, J.T.1
-
51
-
-
27744600091
-
Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression
-
Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol. 2005; 174: 2174-2177.
-
(2005)
J Urol
, vol.174
, pp. 2174-2177
-
-
Osman, I.1
Mikhail, M.2
Shuch, B.3
Clute, M.4
Cheli, C.D.5
Ghani, F.6
-
52
-
-
4243578322
-
Elevated serum HER-2/neu in metastatic prostate cancer
-
Shin BY, Leitzel K, Ali SM et al. Elevated serum HER-2/neu in metastatic prostate cancer. Proc Am Soc Clin Oncol. 2002; 21: 429.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
, pp. 429
-
-
Shin, B.Y.1
Leitzel, K.2
Ali, S.M.3
|